Research progress on comorbidity assessment tools for total joint replacement

doi:10.3877/cma.j.issn.1674-134X.2022.03.014

Abstract

Abstract:

A variety of comorbidities are common in patients undergoing total joint replacement, but research in this area in China is still in the exploratory stage. This article aimed to review the comorbidity assessment tools for total joint replacement and propose suggestions for the selection of assessment tools in clinical practice, with a view to providing reference for the development of domestic clinical and scientific research.

Key words: Arthroplasty, replacement, knee, Arthroplasty, replacement, hip, Comorbidity, Review

Ying Zhang, Juhong Pei, Xiaoli Yin, Ruiling Nan, YeHui Du, Hui Yan, Xinman Dou. Research progress on comorbidity assessment tools for total joint replacement[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2022, 16(03): 348-351.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2022.03.014

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2022/V16/I03/348

References 36

[1]	Aamodt A, Nordsletten L, Havelin LI, et al. Documentation of hip prostheses used in Norway: a critical review of the literature from1996-2000[J]. Acta Orthop Scand, 2004, 75(6): 663-676.
[2]	Cram P, Lu X, Kaboli PJ, et al. Clinical characteristics and outcomes of medicare patients undergoing total hip arthroplasty, 1991-2008[J]. JAMA, 2011, 305(15): 1560-1567.
[3]	Cram P, Lu X, Kates SL, et al. Total knee arthroplasty volume, utilization, and outcomes among medicare beneficiaries, 1991-2010[J]. JAMA, 2012, 308(12): 1227-1236.
[4]	Peter WF, Dekker J, Tilbury C, et al. The association between comorbidities and pain, physical function and quality of Life following hip and knee arthroplasty[J]. Rheumatol Int, 2015, 35(7): 1233-1241.
[5]	Kirkness CS, Mcadam-Marx C, Unni S, et al. Characterization of patients undergoing total hip arthroplasty in a real-world setting and pain related medication prescriptions for management of postoperative pain[J]. J Pain Palliat Care Pharmacother, 2003, 27(3): 235-243.
[6]	Hustedt JW, Goltzer O, Bohl DD, et al. Calculating the cost and risk of comorbidities in total joint arthroplasty in the United States[J]. J Arthroplasty, 2017, 32(2): 355-361.e1.
[7]	Podmore B, Hutchings A, van der Meulen J, et al. Impact of comorbid conditions on outcomes of hip and knee replacement surgery: a systematic review and meta-analysis[J/OL]. BMJ Open, 2018, 8(7): e021784. DOI: 10.1136/bmjopen-2018-021784.
[8]	Sarfati D. Review of methods used to measure comorbidity in cancer populations: no Gold standard exists[J]. J Clin Epidemiol, 2012, 65(9): 924-933.
[9]	Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis[J]. Best Pract Res Clin Rheumatol, 2007, 21(5): 885-906.
[10]	Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J]. J Chronic Dis, 1987, 40(5): 373-383.
[11]	Katz JN, Chang LC, Sangha O, et al. Can comorbidity be measured by questionnaire rather than medical record review？[J]. Med Care, 1996, 34(1): 73-84.
[12]	Librero J, Peiró S, Ordiñana R. Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days[J]. J Clin Epidemiol, 1999, 52(3): 171-179.
[13]	Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index[J]. J Clin Epidemiol, 1994, 47(11): 1245-1251.
[14]	Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data[J]. Med Care, 2005, 43(11): 1130-1139.
[15]	Lakomkin N, Goz V, Lajam CM, et al. Higher modified charlson index scores are associated with increased incidence of complications, transfusion events, and length of stay following revision hip arthroplasty[J]. J Arthroplasty, 2017, 32(4): 1121-1124.
[16]	Piuzzi NS, Strnad GJ, Esa W, et al. The main predictors of length of stay after total knee arthroplasty：patient-related or procedure-related risk factors[J]. J Bone Joint Surg Am, 2019, 101(12): 1093-1101.
[17]	Inacio M, Pratt NL, Roughead EE, et al. Evaluation of three co-morbidity measures to predict mortality in patients undergoing total joint arthroplasty[J]. Osteoarthritis Cartilage, 2016, 24(10): 1718-1726.
[18]	Li WJ, Ayers DC, Lewis CG, et al. Functional gain and pain relief after total joint replacement according to obesity status[J]. J Bone Joint Surg Am, 2017, 99(14): 1183-1189.
[19]	Etcheson JI, Gwam CU, George NE, et al. Patients with major depressive disorder experience increased perception of pain and opioid consumption following total joint arthroplasty[J]. J Arthroplasty, 2018, 33(4): 997-1002.
[20]	Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data[J]. Med Care, 1998, 36(1): 8-27.
[21]	Austin SR, Wong YN, Uzzo RG, et al. Why summary comorbidity measures such as the charlson comorbidity index and elixhauser score work[J]. Med Care, 2015, 53(9): e65-e72.
[22]	Inacio MC, Pratt NL, Roughead EE, et al. Using medications for prediction of revision after total joint arthroplasty[J]. J Arthroplasty, 2015, 30(12): 2061-2070.
[23]	Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data[J]. Med Care, 2012, 50(12): 1109-1118.
[24]	Ondeck NT, Bohl DD, Bovonratwet P, et al. Discriminative ability of elixhauser's comorbidity measure is superior to other comorbidity scores for inpatient adverse outcomes after total hip arthroplasty[J]. J Arthroplasty, 2018, 33(1): 250-257.
[25]	Van Walraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data[J]. Med Care, 2009, 47(6): 626-633.
[26]	Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures[J]. Am J Manag Care, 2006, 12(2): 110-119.
[27]	Groll DL, To T, Bombardier C, et al. The development of a comorbidity index with physical function as the outcome[J]. J Clin Epidemiol, 2005, 58(6): 595-602.
[28]	Groll DL, Heyland DK, Caeser M, et al. Assessment of long-term physical function in acute respiratory distress syndrome (ARDS) patients: comparison of the Charlson Comorbidity Index and the Functional Comorbidity Index[J]. Am J Phys Med Rehabil, 2006, 85(7): 574-581.
[29]	Tolk JJ, Janssen RPA, Haanstra TM, et al. Outcome expectations of total knee arthroplasty patients: the influence of demographic factors, pain, personality traits, physical and psychological status[J]. J Knee Surg, 2020, 33(10)：1034-1040.
[30]	Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model[J]. Med Care, 2003, 41(1): 84-99.
[31]	Johnson ML, Ei SH, Tran TT, et al. Adapting the Rx-Risk-V for mortality prediction in outpatient populations[J]. Med Care, 2006, 44(8): 793-797.
[32]	Inacio MC, Pratt NL, Roughead EE, et al. Predicting infections after total joint arthroplasty using a prescription based comorbidity measure[J]. J Arthroplasty, 2015, 30(10): 1692-1698.
[33]	Cleary PD, Greenfield S, Mulley AG, et al. Variations in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California[J]. JAMA, 1991, 266(1): 73-79.
[34]	Greenfield S, Apolone G, Mcneil BJ, et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement[J]. Med Care, 1993, 31(2): 141-154.
[35]	Inacio MC, Pratt NL, Roughead EE, et al. Comparing co-morbidities in total joint arthroplasty patients using the RxRisk-V, Elixhauser, and Charlson Measures: a cross-sectional evaluation[JOL]. BMC Musculoskelet Disord, 2015, 16(1): 385. DOI: 10.1186/s12891-015-0835-4.
[36]	朱琦，徐栋梁，何沛恒，等.443例初次单侧人工髋关节置换患者术前并存疾病的临床分析[J/CD]．中华关节外科杂志(电子版)，2011，5(3)：324-328.

Please choose a citation manager

Content to export